Are Magic Mushrooms Bad for Your Liver?

Psilocybin, the psychoactive compound in magic mushrooms, does not appear to be toxic to the liver at the doses studied so far. Clinical trials in healthy volunteers have found liver function markers unchanged after psilocybin administration, and a recent animal study specifically looking for liver damage found none. The real liver risk associated with “mushroom poisoning” almost always traces back to a different species entirely, not psilocybin-containing fungi. That said, the science here is younger than many people assume, and there are genuine reasons for caution that go beyond the compound itself.

How the Liver Handles Psilocybin

Psilocybin is what pharmacologists call a prodrug. On its own it does very little. Once you swallow it, enzymes in your gut and liver strip off a phosphate group, converting it into psilocin, the molecule that actually produces psychedelic effects. This conversion happens quickly, and psilocin reaches peak blood levels roughly two to four hours after an oral dose.

From there, the liver does the heavy lifting. Psilocin is broken down primarily by two liver enzymes, CYP2D6 and CYP3A4, with a smaller contribution from an enzyme called monoamine oxidase A. The breakdown products include compounds that are eventually excreted in urine, with psilocin-O-glucuronide being the main urinary metabolite.

² Less than 2% of psilocin leaves the body through the kidneys in its intact form, meaning nearly all of it passes through the liver’s metabolic machinery before being eliminated.³

The elimination half-life of psilocin is short, typically between one and a half and four hours. So the liver’s exposure to the compound is relatively brief. That fast clearance, combined with the low doses used in clinical settings, helps explain why researchers have not observed liver injury in controlled studies.

What Clinical Trials Have Found

In a safety pharmacology study of healthy participants receiving acute psilocybin doses, kidney and liver function parameters were unaltered by the end of the study.⁴ That finding is reassuring but comes with caveats worth spelling out. Clinical trials of psilocybin generally involve one to three doses given days or weeks apart, not daily use over months. The participants are screened beforehand and tend to be physically healthy. So these results tell us that a few moderate doses of psilocybin do not damage a healthy liver over a short period. They do not tell us what happens with frequent or heavy use, or in someone whose liver is already compromised.

The broader clinical trial landscape follows the same pattern. Across studies for depression, anxiety, and obsessive-compulsive disorder, standard blood panels that include liver enzymes like ALT and AST have not flagged problems. But researchers have been looking at liver function as a secondary safety measure, not as the primary focus of these trials. No large study has been designed specifically to track psilocybin’s effects on the liver over time.

An Animal Study That Looked Specifically for Liver Damage

One of the more interesting pieces of evidence comes from a 2025 mouse study that deliberately examined liver tissue after psilocybin exposure. Researchers gave mice psilocybin in the context of an induced liver inflammation model and then examined the liver using multiple staining techniques. They found no noticeable toxic changes in liver tissue at the doses tested and no evidence of hepatotoxicity.⁵

More surprising was what else the study found. In mice whose livers were inflamed using a bacterial toxin called LPS, psilocybin actually reduced the levels of several inflammatory markers. It lowered the expression of pro-inflammatory cytokines including IL-1β, IL-6, and others, with the anti-inflammatory effects being especially pronounced when psilocybin was given after inflammation had already been triggered.⁵ The researchers noted that while psilocybin mushrooms are generally believed to be non-hepatotoxic, they could find no prior conclusive evidence in the literature either confirming or ruling out hepatotoxicity from pure psilocybin. Their study was, in effect, one of the first to look directly at the question with tissue analysis.

It would be premature to call psilocybin “good” for the liver based on one animal study. Mice are not humans, and the doses and routes of administration in laboratory settings do not map neatly onto how people actually consume mushrooms. But the finding that psilocybin did not cause liver damage and may have anti-inflammatory properties in liver tissue is consistent with the broader clinical safety data.

The Real Liver Danger from Mushrooms Has Nothing to Do with Psilocybin

When people hear about mushrooms causing liver failure, they are almost always hearing about a completely different species. In more than 95% of mushroom toxicity cases, poisoning results from misidentification by amateur foragers.⁶ The culprit behind most fatal cases is Amanita phalloides, commonly known as the death cap mushroom. It contains amatoxins, which are powerful hepatotoxins that shut down a critical enzyme in liver cells. The result can be acute liver failure, and it can be lethal.

This distinction is worth emphasizing because confusion between species is a genuine practical risk. Death cap mushrooms can superficially resemble several edible species, and they have been mistaken for psilocybin-containing mushrooms by inexperienced foragers. The timeline of symptoms matters here too. Amatoxin poisoning typically causes gastrointestinal symptoms six or more hours after ingestion, followed by an apparent recovery period before liver damage becomes evident days later.⁷ Psilocybin mushrooms, by contrast, produce their psychoactive effects within about an hour. If you eat what you think is a magic mushroom and feel nothing for many hours before getting violently ill, that is a medical emergency pointing toward a different species entirely.

For anyone foraging rather than obtaining mushrooms from a known source, misidentification is by far the most dangerous liver-related risk. A psilocybin mushroom correctly identified and consumed is, based on everything we know, unlikely to harm your liver. A death cap mushroom mistaken for a psilocybin mushroom can kill you.

Why Clinical Trials Exclude People with Liver Problems

If psilocybin seems safe for the liver, you might wonder why clinical trials routinely screen out people with existing liver disease. A trial protocol for psilocybin in obsessive-compulsive disorder, for example, excludes participants with moderate-to-severe hepatic impairment, defined by elevated liver enzyme levels or bilirubin above certain thresholds.⁸

This exclusion is standard practice in drug development, not a specific red flag for psilocybin. Because the liver is the primary organ responsible for breaking down psilocin, a liver that is not functioning well could metabolize the drug unpredictably. The concern is not that psilocybin will worsen the liver disease but that impaired metabolism could lead to higher-than-expected blood levels of psilocin, potentially intensifying or prolonging the psychedelic experience in ways that are hard to manage in a clinical setting. Until researchers specifically study psilocybin in people with liver impairment, the cautious approach is to exclude them.

This gap in the evidence is worth acknowledging. The safety profile of psilocybin has been established in people with normal liver function. If you have a liver condition, the available data simply does not cover you, and that is different from the data saying it is safe.

Drug Interactions Through Shared Liver Enzymes

Because psilocin is broken down by CYP2D6 and CYP3A4, anything that strongly inhibits or induces those enzymes could change how the body handles psilocybin.⁹ CYP2D6 is particularly active here. In lab experiments using the isolated enzyme, CYP2D6 metabolized nearly all of the psilocin it was exposed to, while CYP3A4 handled about 40%.

This matters for two practical reasons. First, many common medications use the same enzymes. Certain antidepressants, antifungal drugs, and even grapefruit juice can inhibit CYP3A4 or CYP2D6, which could slow the breakdown of psilocin and raise its levels in the blood. The result would not necessarily be liver damage but could mean a stronger or longer trip than expected, which carries its own psychological risks. Second, some people carry genetic variants that make their CYP2D6 enzyme sluggish or nonfunctional. These “poor metabolizers” would clear psilocin more slowly than average, again potentially experiencing more intense effects from the same dose.

None of this is unique to psilocybin. It is the same enzyme-competition issue that shows up with dozens of other drugs. But it is a reason that combining psilocybin with other medications without understanding the interaction carries some unpredictability, and the liver is where that unpredictability plays out.

Contaminants in Wild-Grown Mushrooms

Psilocybin aside, wild mushrooms of any species can accumulate heavy metals from the soil they grow in. A study of dried wild-grown mushrooms available for sale found meaningful concentrations of mercury, cadmium, lead, and arsenic in common species. In one species analyzed, a standard portion of dried mushrooms could deliver up to roughly three-quarters of the maximum recommended daily intake of mercury.¹⁰

That study focused on commercially sold edible mushrooms, not psilocybin species specifically. But the underlying biology is the same: fungi are efficient bioaccumulators, pulling metals from their environment into their fruiting bodies. Psilocybin mushrooms growing in contaminated soil, near roads, or in industrial areas could carry similar loads. Chronic exposure to heavy metals like cadmium and mercury is a well-established cause of liver damage over time. For someone repeatedly consuming wild-foraged mushrooms of any kind, the heavy metal content could pose more of a liver risk than the psilocybin itself.

This is a consideration that rarely comes up in discussions focused on psilocybin’s pharmacology but matters in the real world. The clinical trials that show clean liver panels use pharmaceutical-grade synthetic psilocybin, not ground-up wild mushrooms. The safety profile of the pure compound may not fully translate to the safety profile of mushrooms eaten off the forest floor.

What Remains Unknown

The honest state of the science is that psilocybin looks safe for the liver in the settings where it has been tested, but those settings are narrow. Nearly all the human data comes from one to three supervised doses in healthy adults. The growing population of people who microdose, taking small amounts of psilocybin mushrooms on a regular schedule for weeks or months, is operating well outside the evidence base. Whether chronic low-dose exposure to psilocybin, along with whatever other compounds are present in whole mushrooms, poses any long-term liver risk is an open question that no study has yet addressed.

There is also the matter of dose. Recreational users sometimes consume substantially more than the doses used in clinical research. Higher doses mean more psilocin flowing through the liver per session. While the short half-life suggests the liver’s exposure remains brief even at high doses, the assumption that “no damage at clinical doses” equals “no damage at any dose” is just that: an assumption. The mouse study that found no hepatotoxicity used doses chosen to model therapeutic use, not heavy recreational consumption.

Researchers who have reviewed the literature have been candid about this gap. The authors of the mouse study noted that despite the general belief that psilocybin mushrooms are not hepatotoxic, conclusive evidence in either direction has been lacking.⁵ Their own work begins to fill that gap, but a single mouse study and a handful of clinical trial safety panels do not constitute a comprehensive safety dossier. For now, the absence of evidence of harm is the strongest statement the data supports, and that is a less certain claim than evidence of absence of harm.

Psilocybin’s Anti-Inflammatory Properties and Liver Research

One thread of early research that may surprise people is the possibility that psilocybin could eventually be studied as a treatment for liver inflammation, not a cause of it. In the mouse study discussed earlier, psilocybin reduced the expression of multiple inflammatory markers in liver tissue that had been experimentally inflamed. The reductions were substantial. When given after inflammation was already established, psilocybin lowered IL-1β expression dramatically and reduced IL-6 levels by more than twofold compared to the inflamed control group.⁵

Chronic liver inflammation drives conditions like fatty liver disease and fibrosis, which affect a large portion of the global population. If psilocybin’s anti-inflammatory effects in the liver hold up in further research, it would represent an unexpected twist for a compound most people associate purely with altered states of consciousness. Several psychedelic compounds have shown anti-inflammatory activity in other tissues, so the liver findings fit a broader pattern, though they are far from clinically actionable at this stage. The work is too early to draw therapeutic conclusions, but it does reinforce the picture of psilocybin as a compound that is not inherently hostile to liver cells.

1
PubMed Central. Pharmacokinetics of Psilocybin: A Systematic Review
2
PubMed. Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance
3
PubMed. Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults
4
Neuroscience Applied. Safety pharmacology of acute psilocybin administration in healthy participants
5
PubMed Central. LPS-Induced Liver Inflammation Is Inhibited by Psilocybin and Eugenol in Mice
6
PubMed Central. Acute liver failure caused by mushroom poisoning: a case report and review of the literature
7
Critical Care Medicine. Syndromic diagnosis and management of confirmed mushroom poisonings
8
Frontiers in Psychiatry. Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings
9
PubMed Central. In vitro and in vivo metabolism of psilocybin’s active metabolite psilocin
10
PLOS ONE. Health risk assessment of exposure to toxic elements resulting from consumption of dried wild-grown mushrooms available for sale